Printer Friendly

FDA CLEARS NEXT-GENERATION SURGIMAP 2.0 SOFTWARE.

NEMARIS, Inc. has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the next-generation SURGIMAP 2.0 platform, the preeminent software used to preoperatively plan spine surgery which now offers advanced tools based upon algorithms and the most recent scientific data on the parameters necessary to determine and restore optimal spinal alignment for each patient.

The latest release of SURGIMAP 2.0 features case and image sharing across users facilitated through cloud services as well as multiplatform functionality among PC and Mac operating systems. SURGIMAP 2.0 is used by over 2,000 surgeons worldwide. The software was developed by a group of surgeons, engineers, business leaders, software experts and programmers in order to address the physician need for a user-friendly clinical imaging tool dedicated to spine.

SURGIMAP 2.0 includes the UNiD plug in, jointly developed with one of the company's strategic partners, MEDICREA, (Alternext Paris: FR0004178572-ALMED), a company that specializes in the development of innovative surgical technologies for the treatment of spinal pathologies. The UNiD plug in is embedded into the SURGIMAP 2.0 software interface, and provides surgeons a quick and efficient option for planning and ordering the UNiD rods, the world's first patient-specific spinal osteosynthesis rods, currently available in Europe. MEDICREA's UNiD rod tool eliminates the need to manually contour the rods in the operating room, providing surgeons with a patient specific rod prior to surgery, thus optimizing clinical outcomes and reducing the amount of time patients spend in the operating room. Once the surgery planning is complete, the order is transferred to MEDICREA's UNiD Lab, which processes the request and industrially produces and labels the rod specifically for each patient.

About NEMARIS

NEMARIS Inc (NYC, NY), is the editor of SURGIMAP software. The company was founded in 2008 and has since grown into a team of 20. The company reached profitability in the third quarter of 2014 and expects continued growth in 2015 with the global expansion of healthcare IT. SURGIMAP development was initiated by a group of surgeons, engineers, business leaders, software experts and programmers after they realized that most imaging tools were not user-friendly and not made for the spine specialist. Hence they started with measurement tools, added a DICOM image viewer, a database, and made this all portable so it runs on a USB key, off a mobile device or directly on the web. The SURGIMAP software is free and serves more than 2000 spine surgeon users worldwide. For more information, visit www.surgimapspine.com.

About MEDICREA

MEDICREA is specialized in the design, development, manufacture and distribution of orthopedic implants dedicated to spinal surgery. In a $10 billion market, MEDICREA is a very dynamic small to medium-sized business of 140 employees including 40 people with MEDICREA USA based in New York City - with unique innovation capabilities. Products developed and patented by MEDICREA provide neurosurgeons and orthopedic surgeons specialized in the spine with new and less-invasive surgical solutions that are faster and easier to implement than traditional techniques. The Group's headquarters are based near Lyon, France, and it also has a manufacturing facility for surgical instruments and implants located in La Rochelle as well as three distribution subsidiaries in the USA, the UK and France.

MEDICREA manufactures patient-specific implants, providing the world's first pre-contoured osteosynthesis rod (UNiD rod) utilized in spinal surgery in September 2013 followed by the first ever made-to-measure anterior lumbar interbody device (UNiD ALIF cage) created by 3-D printer in May 2014.

For more information, visit www.medicrea.com or call 646/794-8650.77+.
COPYRIGHT 2014 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Financial Reports
Date:Nov 1, 2014
Words:589
Previous Article:GLOBAL GREEN PETITIONS SEC STOCK SUSPENSION.
Next Article:BRISTOL-MYERS SQUIBB AND LONZA EXPAND AGREEMENT.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters